Global BD&L and Alliance Management

Business Development & Licensing

The MorphoSys Business Development & Licensing team approaches collaborations and licensing deals with the aim of addressing the needs and aligning the contributions of both partners. The ultimate goal for our award-winning BD&L team is to define the combined strengths of such partnerships to create promising therapeutics which make a difference for people suffering from diseases with high unmet medical need. Harboring sound scientific, clinical and drug development knowledge together with an industry-focused expertise in business intelligence, the team lays the groundwork for identifying and evaluating appropriate partners whose assets and expertise present a beneficial and complementary asset to the vast company portfolio.

Currently, we are actively looking for compounds in clinical development that fit into the MorphoSys portfolio. Primary focus are biologics in hemato-oncology and solid tumors. In addition, the team supports MorphoSys’ Research Organization in identifying new targets and technologies to complement the early stage pipeline.

The BD&L Teams are your primary contact for your target, technology and program offers as well in case of interest in our technologies and compounds.

Dr. Anja Hanisch, Senior Director Licensing

Dr. Anja Hanisch, Senior Director Licensing

Dr. Monika Bähner, Senior Director Search & Evaluation / In-Licensing

Dr. Monika Bähner, Senior Director Search & Evaluation / In-Licensing

Thu-Sun
11-14
'20
Jun
Jun

EHA 2020 - 25th Europ. Hematology Association Congress

virtual
Fri-Tue
29-02
'20
May
Jun

ASCO Annual Meeting

Chicago, Illinois, USA
Mon-Thu
03-06
'19
Jun
Jun

BIO International Convention 2019

Philadelphia, U.S.
Fri-Tue
31-04
'19
May
Jun

ASCO Annual Meeting 2019 - American Society of Clinical Oncology

Chicago, Illinois, U.S.
Mon-Wed
25-27
'19
Mar
Mar

Bio-Europe Spring 2019

Vienna, Austria
Mon-Wed
05-07
'18
Nov
Nov

BIO-Europe 2018 Copenhagen

Copenhagen, Denmark
Thu-Sun
14-17
'18
Jun
Jun

EHA 2018 - 23rd Europ. Hematology Association Congress

Stockholm, Sweden
Mon-Thu
04-07
'18
Jun
Jun

BIO International Convention

Boston, USA
Mon-Wed
12-14
'18
Mar
Mar

BIO-Europe Spring 2018 Amsterdam

Amsterdam, Netherlands
Mon-Thu
08-11
'18
Jan
Jan

JP Morgan Healthcare Conference 2018

San Francisco, CA, USA
Sat-Tue
09-12
'17
Dec
Dec

59th ASH Annual Meeting

Atlanta, GA, USA
Mon-Wed
06-08
'17
Nov
Nov

Bio-Europe 2017

Berlin, Germany
Tue-Wed
10-11
'17
Oct
Oct

European Business Development Conference EBDC 2017

Heidelberg, Germany
Mon-Thu
19-22
'17
Jun
Jun

2017 BIO International Convention

San Diego, California, USA
Mon-Thu
09-12
'17
Jan
Jan

35th JPMorgan Conference

San Francisco, CA, USA
Sat-Tue
03-06
'16
Dec
Dec

ASH Annual Meeting 2016

San Diego, CA, USA
Mon-Wed
07-09
'16
Nov
Nov

Bio-Europe

Cologne, Germany
Mon-Wed
04-06
'16
Apr
Apr

BIO-Europe Spring 2016

Stockholm, Sweden
Mon-Thu
11-14
'16
Jan
Jan

J.P. Morgan 34th Annual Healthcare Conference

San Francisco, USA
Mon-Tue
16-17
'15
Nov
Nov

4th Oncology Partnering & Deal-making Conference

San Francisco, CA, USA
Mon-Wed
02-04
'15
Nov
Nov

BIO-Europe 2015

Munich, Germany
Wed-Fri
16-18
'15
Sep
Sep

12th International Pharma Licensing Symposium

Berlin, Germany
Mon
15
'15
Jun

BIO Convention

Philadelphia, USA
Sat-Tue
06-09
'15
Jun
Jun

BIO Convention

San Francisco, USA
Mon-Thu
04-07
'15
May
May

PEGS Boston

Boston, USA
Mon
09
'15
Mar

BIO-Europe Spring

Paris, France

Alliance Management

The negotiation and management of partnerships has been MorphoSys’ foundation and will continue to play an important role also in our future to maximize value creation and serving patients worldwide. The teams are closely integrated within Global BD&L to ensure a smooth transition from contract negotiations into the successful execution of the partnership.

During the complete alliance lifecycle, these teams provide continuous support across all functions, and ensure that respective duties are performed and the partnership is evolving to the full satisfaction of both sides. Our partners benefit from this unit’s performance by receiving the high-quality therapeutic input and reliable technology support they expect from MorphoSys. Not least due to its careful monitoring and coordination work, MorphoSys has one of the broadest and most successful therapeutic pipelines with partners in the industry.

As MorphoSys transitioned into a fully integrated biopharmaceutical company with the establishment of our US-based commercial team in Boston, our expert team was expanded to support also late-stage development and commercialization alliances on both continents.

Dr. Harald Watzka, VP R&D Alliance Management

Dr. Harald Watzka, VP R&D Alliance Management

Dr. Sam White, Director Commercial Alliance Management

Dr. Sam White, Director Commercial Alliance Management

Related Links